Labcorp (LH)
(Delayed Data from NYSE)
$239.05 USD
+4.67 (1.99%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $239.04 -0.01 (0.00%) 7:16 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$239.05 USD
+4.67 (1.99%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $239.04 -0.01 (0.00%) 7:16 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
LabCorp (LH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH
by Urmimala Biswas
Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.
Why Earnings Season Could Be Great for Laboratory Corporation (LH)
by Zacks Equity Research
Laboratory Corporation (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cerner (CERN) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Doximity (DOCS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Doximity's (DOCS) fiscal third-quarter results are likely to reflect growth in its telehealth platform and robust net revenue retention rate.
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Cardiovascular Line Rebounds, Spine Stays Soft
by Zacks Equity Research
Medtronic (MDT) is registering organic growth in the Cardiovascular, Neuroscience and Diabetes segments.
LabCorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by Hologic's (HOLX) Breast Imaging and Interventional Breast Solutions drove Q1 revenues.
What's in Store for Canopy Growth (CGC) in Q3 Earnings?
by Zacks Equity Research
New product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to drive Canopy Growth's (CGC) Q3 top line.
Quest Diagnostics (DGX) Q4 Revenues Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.
Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Robust segmental growth and iTero sales are driving Align Technology's (ALGN) Q4 top line.
Align Technology (ALGN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 6.39% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $273.18 in the latest trading session, marking a +0.08% move from the prior day.
Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Thermo Fisher's (TMO) Q4 earnings surpassed the Zacks Consensus Estimate with strength across the Analytical Instruments segment driving the top line.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.
Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings
by Zacks Equity Research
Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Zacks.com featured highlights include: Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO
by Zacks Equity Research
Crocs, Laboratory Corp. of America, CBRE Group, Tesla and AGCO are included in this blog.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.